Jeremy Cobbold

Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

Peter Eddowes, M. Sasso, Michael Allison et al. · Gastroenterology · 2019 · 1.4K citations · Full text

Medicine, Pathology, Radiology +17

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study

Philip N. Newsome, M. Sasso, Jonathan J Deeks et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 760 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)

Michèle Vacca, Ioannis Kamzolas, Lea Mørch Harder et al. · Nature Metabolism · 2024 · 229 citations · Full text

Medicine, Nutrition, Nutritional Sciences +17

Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study

Yasaman Vali, Jenny Lee, Jérôme Boursier et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 196 citations · Full text

Medicine, Pathology, Diagnostic Pathology +16